Harbour BioMed Partners with Bristol Myers Squibb in $1.1 Billion Multi-Specific Antibody Deal
核心洞察
Harbour BioMed (搜索) announced a multi-year global strategic collaboration with Bristol Myers Squibb (搜索) to discover and develop next-generation multi-specific antibodies for immunology (搜索) and oncology (搜索) applications.
The agreement provides Harbour BioMed (搜索) with $90 million in upfront payments plus potential development and commercial milestones totaling up to $1.035 billion, along with tiered royalties.
The collaboration leverages Harbour BioMed (搜索)'s proprietary Harbour Mice (搜索)® fully human antibody technology platform and HBICE (搜索)® bispecific antibody technology to accelerate multi-specific antibody discovery programs.
Harbour BioMed (搜索) has entered into a multi-year global strategic collaboration and license agreement with Bristol Myers Squibb (搜索) to discover and develop next-generation multi-specific antibodies, the Shanghai-based biopharmaceutical company announced on December 16, 2025. The deal positions both companies to advance innovative antibody therapeutics in immunology (搜索) and oncology (搜索) through combined technological platforms and development expertise.
Financial Terms and Structure
Under the agreement terms, Harbour BioMed (搜索) will receive payments totaling $90 million, with additional development and commercial milestones reaching up to $1.035 billion should Bristol Myers Squibb (搜索) elect to advance all potential programs. The collaboration also includes tiered royalties, creating a comprehensive financial framework that could exceed $1.1 billion in total value.
The partnership structure allows Harbour BioMed (搜索) to collaborate with Bristol Myers Squibb (搜索) to advance and accelerate multi-specific antibody discovery programs, leveraging the combined strengths of both organizations' research and development capabilities.
Technology Platform Integration
The collaboration centers on Harbour BioMed (搜索)'s proprietary Harbour Mice (搜索)® fully human antibody technology platform, which facilitates the efficient discovery and development of innovative biologics with enhanced therapeutic potential. This platform generates fully human monoclonal antibodies (搜索) in both two heavy and two light chains (H2L2) format and heavy chain only (HCAb) format.
Building upon the HCAb antibodies, Harbour BioMed (搜索)'s HCAb-based immune cell engagers (HBICE (搜索)®) bispecific antibody technology delivers tumor-killing effects that are unachievable by traditional combination therapies. The integration of Harbour Mice (搜索)® and HBICE® with a single B cell cloning platform creates a highly unique and efficient antibody discovery engine for developing next-generation therapeutic antibodies.
Strategic Development Approach
The collaboration offers the possibility to utilize Harbour BioMed (搜索)'s established development capabilities to accelerate programs by conducting early clinical trials in China. This approach combines Harbour BioMed's platform strengths with Bristol Myers Squibb (搜索)'s expertise in drug discovery and development to progress programs and deliver transformative therapies to patients worldwide.
"We are delighted to collaborate with Bristol Myers Squibb (搜索) to advance next-generation multi-specific antibody discovery and development," said Jingsong Wang, MD, PhD, Founder, Chairman, and CEO of Harbour BioMed (搜索). "By uniting the strengths of our platform with Bristol Myers Squibb's expertise in drug discovery and development, we look forward to progressing these programs and delivering transformative therapies to patients worldwide."
Company Portfolio Strategy
Harbour BioMed (搜索) is building its robust portfolio and differentiated pipeline through internal R&D capability, collaborations with co-discovery and co-development partners, and select acquisitions. The company focuses on the discovery, development, and commercialization of novel antibody therapeutics in immunology (搜索) and oncology (搜索), with this Bristol Myers Squibb (搜索) partnership representing a significant expansion of its collaborative development strategy.